These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22265265)

  • 1. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
    Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current advances in the treatment of systemic sclerosis.
    Bukiri H; Volkmann ER
    Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
    Jain S; Shahane A; Derk CT
    Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
    Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifibrotics in systemic sclerosis.
    Martin-Lopez M; Carreira PE
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
    Antic M; Distler JH; Distler O
    Curr Opin Pharmacol; 2013 Jun; 13(3):455-62. PubMed ID: 23747024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis.
    Abraham D; Lescoat A; Stratton R
    Mol Aspects Med; 2024 Apr; 96():101252. PubMed ID: 38325132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
    McMahan ZH; Volkmann ER
    Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criteria to select molecular targets for anti-fibrotic therapy.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v12-3. PubMed ID: 18784127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 18. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational drugs for the treatment of scleroderma: what's new?
    Colic J; Campochiaro C; Hughes M; Matucci Cerinic M; Dagna L
    Expert Opin Investig Drugs; 2023; 32(7):601-614. PubMed ID: 37526079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
    Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.